52
J. Am. Chem. Soc. 2000, 122, 52-57
Total Synthesis of (-)-Steganone Utilizing a Samarium(II) Iodide
Promoted 8-Endo Ketyl-Olefin Cyclization
Lauren G. Monovich,† Yvan Le Hue´rou,†,‡ Magnus Ro1nn,† and Gary A. Molander*,†,‡
Contribution from the Department of Chemistry and Biochemistry, UniVersity of Colorado, Boulder,
Colorado 80309-0215, and Roy and Diana Vagelos Laboratories, Department of Chemistry, UniVersity of
PennsylVania, Philadelphia, PennsylVania 19104-6323
ReceiVed August 18, 1999
Abstract: A six-step synthesis of (()-steganone from commercially available 3,4,5-trimethoxybenzyl alcohol
features a samarium(II) iodide promoted 8-endo ketyl-olefin coupling to install, in a single transformation,
the 8,5 ring system common to the lignan lactones. The racemic synthesis provided the basis for the construction
of (-)-steganone, which exploited a chromium tricarbonyl moiety both to establish and protect the desired
absolute stereochemistry through key transformations, including a SmI2-promoted 8-endo radical cyclization
and two palladium-catalyzed couplings.
Introduction
The 1973 article describing the isolation of steganone and
steganacin (Figure 1) marked them as biologically active targets1
and initiated synthetic studies culminating in the first published
total syntheses in 1976.2,3 Steganone continued to be a popular
target through the next two decades because some natural and
synthetic congeners of steganone, steganacin, and stegane inhibit
tubulin polymerization both in vitro and in vivo.4 Structure-
activity relationships of synthetic congeners and new isolates
continue to be investigated on steganone analogues.5 Many
synthetic studies have been conducted on these compounds and
to date, nine total syntheses of steganone have been achieved.
Two syntheses,6,7 based on significant advances in stereoselec-
tive biaryl couplings, provided a fresh perspective on the
construction of (-)-steganone. Both relied on a previously
developed sequence to generate the 8-5 ring system.8 To date,
no synthesis has featured a radical ring closure to form the eight-
membered ring and in all cases formation of the five- and eight-
Figure 1. Cyclooctadiene lignan lactones steganone and steganacin.
membered rings is separated by several synthetic transforma-
tions. Consequently, the 8-5 ring system of steganone presented
itself as an appropriate challenge with which to explore the
SmI2-promoted 8-endo ketyl-olefin radical cyclization in total
synthesis.
Previous racemic syntheses of steganone reveal that the eight-
membered ring can be generated by ring-expansion or ring-
closing methods. Ring expansion from a 6,4 ring system
produced by [2+2] cycloaddition to a phenanthroline unit2,9 or
an imaginative ring expansion from a 7,3 ring system10 both
yield substituted eight-membered rings requiring further elabo-
ration to install the lactone ring of steganone. Ring-closing
methods are represented by an alkylation, which generates the
eight-membered ring after intermolecular biaryl coupling,8,11 and
by an intramolecular biaryl coupling,3,12 which forms the eight-
* To whom correspondence should be addressed at the University of
Pennsylvania.
† University of Colorado.
‡ University of Pennsylvania.
(1) Kupchan, S. M.; Britton, R. W.; Zeigler, M. F.; Gilmore, C. J.;
Restivo, R. J.; Bryan, R. F. J. Am. Chem. Soc. 1973, 95, 1335.
(2) Hughes, L. R.; Raphael, R. A. Tetrahedron Lett. 1976, 1543.
(3) Kende, A. S.; Liebeskind. L. S. J. Am. Chem. Soc. 1976, 98, 267.
(4) (a) Tomioka, K.; Ishiguro, T.; Mizuguchi, H.; Komeshima, N.; Koga,
K.; Tsukagoshi, S.; Tsuruo, T.; Tashiro, T.; Tanida, S.; Kishi, T. J. Med.
Chem. 1991, 34, 54. (b) Wang, R. W.-J.; Rebhun, L. I.; Kupchan, S. M.
Cancer Res. 1977 37, 3071. (c) Zavala, F.; Guenard, D.; Robin, J.-P.; Brown,
E. J. Med. Chem. 1980, 23, 546. (d) Wickramaratne, D. B. M.; Pengsuparp,
T.; Mar, W.; Chai, H. B.; Chagwedera, T. E.; Beecher, C. W. W.;
Farnsworth, N. R.; Kinghorn, A. D.; Pezzuto, J. M.; Cordell, G. A. J. Nat.
Prod. 1993, 56, 2083. (e) Dhal, R.; Brown, E.; Robin, J.-P. Tetrahedron
1983, 39, 2787. (f) Ayres, D. C.; Loike, J. D. Chemistry & Pharmocology
of Natural Products; Lignans: Chemical, Biological, and Clinical Proper-
ties; Cambridge University Press: Cambridge; New York, 1990.
(5) Bradley, A.; Motherwell, W. B.; Ujjainwalla, F. J. Chem. Soc., Chem.
Commun. 1999, 10, 917.
(9) (a) Becker, D.; Hughes, L. R.; Raphael, R. A. J. Chem. Soc., Perkin
Trans. 1 1977, 1674. (b) Krow, G. R.; Damodaran, K. M.; Michener, E.;
Wolf, R.; Guare, J. J. Org. Chem. 1978, 43, 3950. (c) Larson, E. R.; Raphael,
R. A. Tetrahedron Lett. 1979, 5041. (d) Narasimhan, N. S.; Aidhen, I. S.
Tetrahedron Lett. 1988, 29, 2987. (e) Aidhen, I. S.; Narasimhan, N. S. Indian
J. Chem., Sect. B 1993, 32B, 211.
(10) (a) Magnus, P.; Schultz, J.; Gallagher, T. J. Chem. Soc., Chem.
Commun. 1984, 1179. (b) Magnus, P.; Schultz, J.; Gallagher, T. J. Am.
Chem. Soc. 1985, 107, 4984.
(6) Meyers, A. I.; Flisak, J. R.; Aitken, R. A. J. Am. Chem. Soc. 1987,
109, 5446.
(7) Uemura, M.; Daimon, A.; Hayashi, Y. J. Chem. Soc., Chem. Commun.
1995, 19, 1943.
(8) Ziegler, F. E.; Fowler, K. W.; Sinha, N. D. Tetrahedron Lett. 1978,
2767.
(11) (a) Brown, E.; Dhal, R.; Robin, J.-P. Tetrahedron Lett. 1979, 733.
(b) Mervic, M.; Ben-David, Y.; Ghera, E. Tetrahedron Lett. 1981, 22, 5091.
(c) Ziegler, F. E.; Chliwner, I.; Fowler, K. W.; Kanfer, S. J.; Kuo, S. J.;
Sinha, N. D. J. Am. Chem. Soc. 1980, 102, 790. (d) Dhal, R.; Brown, E.;
Robin, J.-P. Tetrahedron 1983, 39, 2787.
(12) Ziegler, F. E.; Schwartz, J. A. J. Org. Chem. 1978, 43, 985.
10.1021/ja9930059 CCC: $19.00 © 2000 American Chemical Society
Published on Web 12/22/1999